Aarhus, Denmark (UroToday.com) Dr. Ming-Jun Shi from the Institut Curie in Paris discussed the role of FGFR3 mutations using an in vivo murine model. Human FGFR3IIIb carrying an S249C mutation was transduced into the urothelium of mice using the 5’ regulatory region of the mouse uroplakin II promoter. Dr. Shi noted that bladders from mice aged 1-24 months were examined for macroscopic lesions and underwent histopathologic evaluation. Urothelial hyperplasia was noted, in addition to spontaneous low-grade papillary tumor formation. Whole exome sequencing and DNA-array based analyses were also performed and found that murine in vivo models resembled the luminal-papillary subtype of bladder cancer, with poor immune infiltration. Given the similarity of this murine model to human bladder tumors, it may provide a novel way to investigate therapies in vivo.

Abstract take-home message:

  •  FGFR3 mutations can be investigated in an in vivo murine model and resemble a luminal-papillary human subtype

Presented by: Ming-Jun Shi, MD, Ph.D., Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France, Paris-Sud University, Paris-Saclay University, Paris, France, Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Written by Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.